Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Allergy & Immunology
•
Pulmonology
•
Asthma
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
Related Questions
Are there any immunosuppressive agents that have been shown to have utility in concurrent idiopathic anaphylaxis?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?
Does the presence of calcified granulomas on chest imaging influence your choice of biologic for treatment of psoriatic arthritis (or rheumatoid arthritis)?
What are best practices in management of severe acute infusion reaction from infliximab?
Are you comfortable with using NSAIDs in a patient on methotrexate for inflammatory arthritis?
What is your approach to inhaler therapy in a patient with asthma who cannot be on an inhaled corticosteroid due to ocular disease?
Is there a role for nitazoxanide for treatment of norovirus gastroenteritis in immunocompromised patients?
What is your approach to counseling patients regarding re-initiation of anti-TNF therapy after completion of treatment for non-disseminated pulmonary histoplasmosis?
Is methacholine challenge on its way out?
